Orgenesis (OTCQB: ORGS) is a biotechnology company specializing in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry, according to the company’s website (see here: www.orgenesis.com). SNNLive caught up with Vered Caplan, CEO of Orgenesis Inc. at the BIO CEO & Investor Conference 2019 in New York, NY.
The interview starts off with an overview and summary of Orgenesis, and followed by highlights from the last 6-12 months. Vered then goes on to discuss where the company is at in their clinical development and why it’s important to have industrialization for cell therapies earlier in clinical-stage company’s life cycles.
Our host then asks what makes Orgenesis unique when compared to their peers, the company’s IP portfolio, and Ms. Caplan’s background. The interview closes out with a discussion of the company’s growth drivers for 2019.
For more information about Orgenesis Inc., please visit: www.orgenesis.com
The interview may contain forward-looking statements about Orgenesis Inc. See Orgenesis Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.
Please read our full disclosure here.